Abstract: A display screen generation apparatus includes: an acquisition portion acquiring for each of a plurality of print products produced through a plurality of processes, progress of the processes; and a display portion generating a display screen that displays for each of the plurality of print products, the process waiting to be executed, the process being executed, the process already executed, and the process not intended to be executed in a distinguishable manner from each other.

Abstract: A self-service POS terminal device comprises a first antenna and a second antenna, and reads, via each of the first antenna and the second antenna, commodity-related information stored in IC tags of commodities. The first antenna is positioned at a position for reading the IC tags of the commodities loaded in a shopping basket at a prescribed position, and forms a first reading area. The second antenna is positioned at a position for reading the IC tags of the commodities taken out from the shopping basket at the prescribed position and put into a shopping bag, and forms a second reading area.

Abstract: A self-service POS terminal device comprises a first antenna and a second antenna, and reads, via each of the first antenna and the second antenna, commodity-related information stored in IC tags of commodities. The first antenna is positioned at a position for reading the IC tags of the commodities loaded in a shopping basket at a prescribed position, and forms a first reading area. The second antenna is positioned at a position for reading the IC tags of the commodities taken out from the shopping basket at the prescribed position and put into a shopping bag, and forms a second reading area.

Abstract: To provide a compound and a tumor therapeutic agent which are highly effective in cancer therapy and are less likely to cause hypertension as a side effect, and to provide development of a drug for elucidating the action mechanism of lenvatinib to help further development of new drugs. The lenvatinib derivative of the present invention comprises a compound represented by the following chemical structural formula (1) (wherein R represents an alkylene group which may have a branch) and a salt thereof, and a solvate thereof. This derivative has a nitric acid ester group, and thus produces nitric oxide (NO) having a vasodilating action in vivo, so that a higher-concentration lenvatinib component can be expected to arrive at target molecules present in cancer cells and vascular endothelial cells on the host side and also can suppress hypertension as a side effect.

Abstract: A support device for a portable terminal includes a placement portion configured to place a portable terminal having a hand belt mounted to a back surface of the portable terminal and configured to receive a user's hand. The placement portion includes: a terminal placement surface configured to support the back surface of the portable terminal; and a belt-receiving recessed portion, which has a shape recessed with respect to the terminal placement surface in a direction perpendicular to the terminal placement surface and is configured to receive the hand belt of the portable terminal placed on the placement portion. The support device for a portable terminal is configured to support the portable terminal placed on the placement portion under a state in which the portable terminal is inclined rearward.

Abstract: A support device for a portable terminal includes a placement portion configured to place a portable terminal having a hand belt mounted to a back surface of the portable terminal and configured to receive a user's hand. The placement portion includes: a terminal placement surface configured to support the back surface of the portable terminal; and a belt-receiving recessed portion, which has a shape recessed with respect to the terminal placement surface in a direction perpendicular to the terminal placement surface and is configured to receive the hand belt of the portable terminal placed on the placement portion. The support device for a portable terminal is configured to support the portable terminal placed on the placement portion under a state in which the portable terminal is inclined rearward.

Abstract: A novel agent which is effective in the prevention or treatment of a chronic respiratory disease such as COPD, interstitial pneumonia and asthma is provided. The therapeutic agent for a chronic respiratory disease comprises, as an active ingredient, a hydroquinone derivative represented by general formula (1) wherein R1 represents an alkyl group having 4 to 8 carbon atoms, and R2 represents a hydrogen atom, an alkylcarbonyl group having 2 to 6 carbon atoms or an alkoxycarbonyl group having 2 to 6 carbon atoms.

Abstract: The disclosure relates to compositions, methods and systems for improving blood circulation and/or for the treatment of acute poor circulation of the liver, kidneys, heart, brain, and other organs utilizing highly concentrated tocotrienols/tocotrienol derivatives. The compositions, methods and systems of the disclosure may also be applicable in the treatment of chronic tissue hypoxemia, organ damage as a result of cell death, dementia, ulceration of the skin, and other such internal organ/brain/skin failure.

Abstract: A semiconductor device is provided, which includes an annular insulation separation portion penetrating a semiconductor substrate, and an electrode penetrating the semiconductor substrate in a region surrounded by the annular insulation separation portion, wherein the insulation separation portion includes at least a first film that gives compressive stress in a depth direction on the side of a substrate, a second film that gives tensile stress in the depth direction is formed on the first film, and film thicknesses of the first and second films are adjusted so that the compressive stress and the tensile stress are almost balanced.

Abstract: A method of manufacturing a semiconductor device wherein a film containing Si and Ge is formed on a conducting film over a substrate by using a raw material gas containing Si and a raw material gas containing Ge, includes: forming Si nuclei on the conducting film at a first ratio of a flow rate of the raw material gas containing Ge to a flow rate of the raw material gas containing Si; and forming, on the Si nuclei, a film having Si and Ge at a second ratio of the flow rate of the raw material gas containing Ge to the flow rate of the raw material gas containing Si, the second ratio being greater than the first ratio.

Abstract: A semiconductor device is provided, which includes an annular insulation separation portion penetrating a semiconductor substrate, and an electrode penetrating the semiconductor substrate in a region surrounded by the annular insulation separation portion, wherein the insulation separation portion includes at least a first film that gives compressive stress in a depth direction on the side of a substrate, a second film that gives tensile stress in the depth direction is formed on the first film, and film thicknesses of the first and second films are adjusted so that the compressive stress and the tensile stress are almost balanced.

Abstract: A manufacturing method of a semiconductor device is provided, comprising: loading a substrate into a processing chamber; forming a first film on the substrate by supplying silicon atom-containing gas, boron atom-containing gas, and germanium atom-containing gas into the processing chamber; forming a second film on the first film by supplying the silicon atom-containing gas and the boron atom-containing gas into the processing chamber; and unloading the substrate from the processing chamber.

Abstract: A manufacturing method of a semiconductor device is provided, comprising: loading a substrate into a processing chamber; forming a first film on the substrate by supplying silicon atom-containing gas, boron atom-containing gas, and germanium atom-containing gas into the processing chamber; forming a second film on the first film by supplying the silicon atom-containing gas and the boron atom-containing gas into the processing chamber; and unloading the substrate from the processing chamber.

Abstract: The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.

Abstract: The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.

Abstract: A compound is prepared based on Formula 1: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms.

Abstract: The progression of hepatic fibrosis and hepatic cirrhosis caused by various hepatic disorders and damages such as chronic hepatitis can be restrained by hepatic fibrosis inhibitor containing a compound represented by the following chemical formula: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6, or alkoxycarbonyl group with a carbon number of 2 to 6.

Abstract: A compound is prepared based on Formula 1: wherein, R1 represents an alkyl group with a carbon number of 4 to 8, and R2 represents a hydrogen atom, alkylcarbonyl group with a carbon number of 2 to 6 or alkoxycarbonyl group with a carbon number of 2 to 6. A curative drug for neurodegenerative diseases can be prepared principally from the compound or a hydroquinone derivative consisting of a cyclodextrin inclusion compound thereof. The curative drug for neurodegenerative diseases has a safe and beneficial effect of inhibiting nerve cell disorder due to oxidative stress, thereby to stop progression of symptoms.

Abstract: The present invention is concerned with an anti-inflammation analgesic preparation which contains a specific 3-0-substituted ascorbic acid as an active ingredient, shows excellent anti-inflammation analgesic effects and is excellent in shelf life, safety to a skin and endermic absorptivity of the active ingredient.